IPCALAB vs SUNPHARMA: Stock Comparison

IPCA LABORATORIES vs SUN PHARMACEUTICAL IND LUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. IPCA LABORATORIES shows a lower P/E, a higher ROE and lower leverage, while SUN PHARMACEUTICAL IND L shows a higher dividend yield, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

IPCALAB leads 5; SUNPHARMA leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

IPCALABSUNPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹49,853 Cr
₹4.56 L Cr
P/E RatioIPCALAB has the lower reading
37.87x
38.35x
P/B RatioSUNPHARMA has the lower reading
6.15x
5.55x
EPSSUNPHARMA has the higher reading
₹14.71
₹50.42
Book ValueContext only
₹375.4
₹348.31
Dividend YieldSUNPHARMA has the higher reading
0.31%
0.83%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.56 L Cr vs ₹49,853 Cr
P/E Ratio
IPCALAB has a lower P/E
37.87x vs 38.35x
P/B Ratio
SUNPHARMA has a lower P/B
5.55x vs 6.15x
EPS
SUNPHARMA has higher earnings per share
₹50.42 vs ₹14.71
Dividend Yield
SUNPHARMA has a higher dividend yield
0.83% vs 0.31%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 6.2%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs 25.6%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
166.5% vs -23.99%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricIPCALABSUNPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricIPCALABSUNPHARMA
Live Price₹1,965.3₹1,899
Day Change0.47%-0.89%
Volume80,4017.61 L
52-Week High₹2,001.5₹2,046.9
52-Week Low₹1,251.6₹1,548
Distance from 52W High-1.81%-7.23%

Valuation

MetricIPCALABSUNPHARMA
Market Cap₹49,853 Cr₹4.56 L Cr
P/E Ratio37.87x38.35x
P/B Ratio6.15x5.55x
EPS₹14.71₹50.42
Book Value₹375.4₹348.31
Dividend Yield0.31%0.83%

Growth

MetricIPCALABSUNPHARMA
Revenue Growth (TTM YoY)6.2%12.8%
EPS Growth (TTM YoY)341.6%25.6%
Qtr Sales Growth-23.99%166.5%
Qtr Profit Growth-12.02%160.17%

Profitability & Leverage

MetricIPCALABSUNPHARMA
ROE14.19%11.76%
ROCE14.74%9.6%
Net Margin11.83%18.56%
Operating Margin21.48%22.81%
Debt to Equity0.03x0.6x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricIPCALABSUNPHARMA
Promoter Holding44.72%54.48%
FII Holding10.73% 0.1 pp14.53% 1.4 pp
DII Holding37.37% 0.08 pp22.18% 1.07 pp
Public Holding7.18% 0.02 pp8.81% 0.33 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA LABORATORIES and SUN PHARMACEUTICAL IND L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.